Globus Medical Inc stock (US3795772082): valuation metrics in focus after robotics leasing update

Globus Medical Inc shares traded broadly steady on the New York Stock Exchange on Friday, with the United States-based medical device group remaining in focus after commentary on its transition toward leasing and rental models for its Excelsius surgical robotics platform highlighted the potential for higher recurring revenue and implications for valuation multiples, according to a Zacks-related note published on 05/28/2026 that discussed the company’s enabling technologies strategy and recurring revenue ambitions.Zacks/TradingView as of 05/28/2026

The stock traded at about USD 82.45 on 05/29/2026 on the NYSE under the ticker GMED, implying an equity value near USD 11.2 billion for the Pennsylvania-headquartered company, according to screening data that also put the shares on a trailing price-to-earnings ratio around 18.9 times and a price-to-sales multiple close to 3.8 times.WallStreetZen as of 05/29/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Globus Medical Inc: core business model

Globus Medical Inc develops spine and orthopedic implants alongside enabling technologies such as the Excelsius line of surgical robots, with revenue largely generated by procedure-driven implant sales and a growing contribution from technology platforms that can be commercialized through capital sales, leases, rentals and service arrangements.

Valuation metrics and multiples for Globus Medical Inc

With a market capitalization in the area of USD 11.2 billion at a share price of roughly USD 82.45 as of 05/29/2026, Globus Medical Inc currently trades on valuation metrics that position it in the mid-to-upper range of the medical devices peer set, reflecting both its core spine franchise and expectations for growth from robotics and trauma offerings.WallStreetZen as of 05/29/2026

Screening data points to a trailing price-to-earnings ratio near 18.9 times and an enterprise-value-to-sales multiple of just under 4 times for the latest reported period, levels that sit below some high-growth medtech names but above more mature diversified healthcare companies, while the company does not currently pay a regular cash dividend and therefore offers a dividend yield of 0.0 percent.WallStreetZen as of 05/29/2026

The evolving mix between traditional implant sales and higher-margin, more recurring technology revenues from robotics and navigation systems is central to how investors frame the appropriate earnings and sales multiples for the stock, especially as the leasing and rental-led approach to monetizing Excelsius platforms could smooth revenue recognition compared with one-time capital equipment sales, according to the late-May 2026 Zacks-linked update on the company’s strategy.Zacks/TradingView as of 05/28/2026

Conclusion

Globus Medical Inc’s steady share price on 05/29/2026 comes as investors continue to assess its transition toward leasing and rental models for Excelsius robotics and the implications for the stability and mix of revenue. The current valuation, with a trailing price-to-earnings ratio just below 20 times and no dividend, suggests the market is balancing growth from spine, trauma and enabling technologies against sector competition and execution on the new monetization model. How effectively the company converts its installed base and procedure volumes into recurring robotics-related revenue streams will likely remain central to how its earnings and sales multiples evolve within the broader U.S. medical devices universe.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.